Abstract
A huge number of autoantibodies are detected during the clinical encounter of Guillain-Barré syndrome (GBS) and its variants. The autoantibodies sensitivity and specificity are not always sufficient, especially in demyelinating GBS, where they have not yet been identified in most cases. Autoantibody results may mislead the diagnosis if the limitations of the test are not understood. Therefore, if there is any doubt about the interpretation of the results, clinicians should be careful in accurately understanding them by making inquiries to specialists.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
